nach oben

Erschienen in:

01.06.2006 | Review

Anti-inflammatory and immunosuppressive drugs and reproduction

verfasst von: Monika Østensen, Munther Khamashta, Michael Lockshin, Ann Parke, Antonio Brucato, Howard Carp, Andrea Doria, Raj Rai, Pierluigi Meroni, Irene Cetin, Ronald Derksen, Ware Branch, Mario Motta, Caroline Gordon, Guillermo Ruiz-Irastorza, Arsenio Spinillo, Deborah Friedman, Rolando Cimaz, Andrew Czeizel, Jean Charles Piette, Ricard Cervera, Roger A Levy, Maurizio Clementi, Sara De Carolis, Michelle Petri, Yehuda Shoenfeld, David Faden, Guido Valesini, Angela Tincani

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Rheumatic diseases in women of childbearing years may necessitate drug treatment during a pregnancy, to control maternal disease activity and to ensure a successful pregnancy outcome. This survey is based on a consensus workshop of international experts discussing effects of anti-inflammatory, immunosuppressive and biological drugs during pregnancy and lactation. In addition, effects of these drugs on male and female fertility and possible long-term effects on infants exposed to drugs antenatally are discussed where data were available. Recommendations for drug treatment during pregnancy and lactation are given.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4: 295-306. 10.1111/j.1538-7836.2006.01753.x.PubMed

Nielsen GL, Sorensen HT, Larsen H, Pedersen L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J. 2001, 322: 266-270.

Chan LY, Yuen PM: Risk of miscarriage in pregnant users of NSAIDs. More information is needed to be able to interpret study's results. Br Med J. 2001, 322: 1365-1366.

Li DK, Liu L, Odouli R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J. 2003, 327: 368-373.

Kozer E, Moldovan Costei A, Boskovic R, Nulman I, Nikfar S, Koren G: Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 70-84. 10.1002/bdrb.10002.PubMed

Yussoff Dawood M: Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993, 169: 1255-1265.

Lewis RB, Schulman JD: Influence of acetylicsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet. 1973, ii: 1159-1161. 10.1016/S0140-6736(73)92934-6.

Sawdy RJ, Lye S, Fisk NM, Bennett PR: A double-blind ran-domised study of fetal side effects during and after short-term maternal administration of indomethacin, sulindac, and nimesulide for therapy of preterm labor. Am J Obstet Gynecol. 2003, 188: 1046-1051. 10.1067/mob.2003.255.PubMed

Locatelli A, Vergani P, Bellini P, Strobelt N, Ghidini A: Can a cyclooxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?. BJOG. 2001, 108: 325-326. 10.1016/S0306-5456(00)00071-1.PubMed

10.

Stika CS, Gross GA, Leguizamon G, Gerber S, Levy R, Mathur A, Bernhard LM, Nelson DM, Sadovsky Y: A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol. 2002, 187: 653-660. 10.1067/mob.2002.125281.PubMed

11.

Cook JC, Jacobson CF, Gao F, Tassinari MS, Hurtt ME, DeSesso JM: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 5-26. 10.1002/bdrb.10005.PubMed

12.

Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003, 68: 47-56. 10.1002/bdrb.10008.PubMed

13.

Heinonen OP, Slone D, Shapiro S: Birth Defects and Drugs in Pregnancy. 1977, Littleton, MA: Littleton Publishing Sciences Group, 286-295.

14.

Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S: Aspirin and congenital malformations. Lancet. 1976, ii: 1373-1375. 10.1016/S0140-6736(76)93025-7.

15.

Briggs GG, Freeman RK, Yaffe SJ, eds: Drugs in Pregnancy and Lactation. 2002, Philadelphia: Lippincott Williams & Wilkins, 6

16.

Källèn B: The teratogenicity of antirheumatic drugs – what is the evidence?. Scand J Rheumatol. 1998, 27 (Suppl 107): 119-124.

17.

Kozer E, Shekoufeh N, Costei A, Boskovic R, Nulman I, Koren G: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002, 187: 1623-1630. 10.1067/mob.2002.127376.PubMed

18.

Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L: Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology. 1997, 56: 241-243. 10.1002/(SICI)1096-9926(199710)56:4<241::AID-TERA2>3.0.CO;2-1.PubMed

19.

Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, Khan KN: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res A Clin Mol Teratol. 2003, 67: 54-58. 10.1002/bdra.10032.PubMed

20.

Momma K, Takeuchi H: Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins. 1983, 26: 631-643. 10.1016/0090-6980(83)90200-9.PubMed

21.

Norton ME, Merril J, Cooper BAB, Kuller JA, Clyman RI: Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993, 329: 1602-1607. 10.1056/NEJM199311253292202.PubMed

22.

Vermillion ST, Scardo JA, Lashus AG, Wiles HB: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol. 1997, 177: 256-261. 10.1016/S0002-9378(97)70184-4.PubMed

23.

Van den Veyver IB, Moise KJ, Ou CN, Carpenter RJ: The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet Gynecol. 1993, 82: 500-503.PubMed

24.

Norton ME: Fetal effects of indomethacin administration during pregnancy. Teratology. 1997, 56: 282-292. 10.1002/(SICI)1096-9926(199710)56:4<282::AID-TERA7>3.0.CO;2-0.PubMed

25.

Alano MA, Ngougmna E, Ostrea EM, Konduri GG: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 2001, 107: 519-513. 10.1542/peds.107.3.519.PubMed

26.

Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA: The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol. 1989, 160: 1525-1531.PubMed

27.

van der Heijden B, Gubler MC: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol. 1995, 9: 675-10.1007/BF00860975.PubMed

28.

Llanas B, Cavert MH, Apere H, Demarquez JL: Les effets sec-ondaires du ketoprofène après exposition intra-utérine. Intérêt du dosage plasmatique. Arch Pediatr. 1996, 3: 248-253. 10.1016/0929-693X(96)81303-0.PubMed

29.

Peruzzi L, Gianooglio B, Porcellini G, Conti G, Amoro A, Coppo R: Neonatal chronic kidney failure associated with cyclooxy-genase-2 inhibitors administered during pregnancy. Minerva Uro Nefrol. 2001, 53: 113-116.

30.

Stuart MJ, Gross SJ, Elrad H, Graeber JE: Effects of acetylsali-cylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 1982, 307: 909-912.PubMed

31.

Hertz-Picciotto I, Hopenhayn-Rich C, Golub M, Hooper K: The risks and benefit of taking aspirin during pregnancy. Epidemiol Rev. 1990, 12: 108-148.PubMed

32.

Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM: Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994, 171: 892-900.PubMed

33.

Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW: Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003, 111: e77-e81. 10.1542/peds.111.1.e77.PubMed

34.

Horlocker TT, Bajwa ZH, Ashraf Z, Khan S, Wilson JL, Sami N, Peeters-Asdourian C, Powers CA, Schroeder DR, Decker PA, et al: Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection. Anesth Analg. 2002, 95: 1691-1697. 10.1097/00000539-200212000-00041.PubMed

35.

Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK: Comparative analysis of pharmacologic and/or geneticdisruption of cyclooxygenase-1 and cyclooxygenase-2 function infemale reproduction in mice. Endocrinology. 2001, 142: 3198-3206. 10.1210/en.142.7.3198.PubMed

36.

Sookvanichsilp N, Pulbutr P: Anti-implantation effects ofindomethacin and celecoxib in rats. Contraception. 2002, 65: 373-378. 10.1016/S0010-7824(01)00322-5.PubMed

37.

Mendonca LLF, Khamashta MA, Nelson-Piercy C, Hughes GRV: Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology. 2000, 39: 880-882. 10.1093/rheumatology/39.8.880.PubMed

38.

Uhler ML, Hsu JW, Fisher SG, Zinaman MJ: The effect ofnons-teroidal antiinflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001, 76: 957-961. 10.1016/S0015-0282(01)02829-1.PubMed

39.

Pall M, Friden BE, Brannstrom M: Induction of delayedfollicular rupture in the human by the selective COX-2 inhibitor rofe-coxib: a randomized double blind study. Hum Reprod. 2001, 16: 1323-1328. 10.1093/humrep/16.7.1323.PubMed

40.

Martini AC, Molina RI, Tissera AD, Ruiz RD, DeCuneo MF: Analysis of semen from patients chronically treated with low or moderate doses of aspirin like drugs. Fertil Steril. 2003, 80: 221-222. 10.1016/S0015-0282(03)00550-8.PubMed

41.

Østensen M: Safety of non-steroidal anti-inflammatorydrugs during pregnancy and lactation. Inflammopharmacology. 1996, 4: 31-41.

42.

Spigset O, Hägg S: Analgesics and breast-feeding. Safety considerations. Paediatr Drugs. 2000, 2: 223-238. 10.2165/00128072-200002030-00006.PubMed

43.

Committee on Drugs. American Academy of Pediatrics: The transfer of drugs and other chemicals into human milk. Pediatrics. 2001, 108: 776-789.

44.

Derksen RHW, Khamashta MA, Branch DW: Management of theobstetric antiphospholipid syndrome. Arthritis Rheum. 2004, 50: 1028-1039. 10.1002/art.20105.PubMed

45.

Empson M, Lassere M, Craig J, Scott J: Prevention ofrecurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant [review]. Cochrane Database Syst Rev. 2005, 2: CD002859-PubMed

46.

Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptorantagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003, 3: 23-10.2165/00129784-200303060-00005.

47.

The Matisse Investigators: Subcutaneous Fondoparinuxversus intravenous unfractioned heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003, 349: 1695-1702. 10.1056/NEJMoa035451.

48.

Turpie AG, Eriksson BI, Bauer KA, Lassen MR: New pentasac-charides for the prophylaxis of venous thromboembolism. Chest. 2003, 124: 371S-378S. 10.1378/chest.124.6_suppl.371S.PubMed

49.

Dempfle CEH: Minor transplacental passage of fondoparinux in vivo. N Engl J Med. 2004, 350: 1914-1915. 10.1056/NEJM200404293501825.PubMed

50.

Olsson SB Executive Steering Committee on behalf of the SPORTIF III investigators: Stroke prevention with the oral direct thrombion inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003, 362: 1691-1698. 10.1016/S0140-6736(03)14841-6.

51.

Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, THRIVE Treatment Study Investigators: Ximelagatran vs low-molecular-weight heparin and war-farin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005, 293: 681-689. 10.1001/jama.293.6.681.PubMed

52.

Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, EXULT A Study Group: Comparison ofximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003, 349: 1703-1712. 10.1056/NEJMoa035162.PubMed

53.

Benediktsson R, Calder AA, Edwards CRW, Seckl JR: Placental 11b-hydroxysteroid dehydrogenase: a key regulatorof fetal glucocorticoid exposure. Clin Endocrinol. 1997, 46: 161-166. 10.1046/j.1365-2265.1997.1230939.x.

54.

Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L: Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing pred-nisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992, 166: 1318-1323.PubMed

55.

Pinsky L, DiGeorge AM: Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science. 1965, 147: 402-403.PubMed

56.

Reinisch JM, Simon NG: Prenatal exposure to prednisone inhumans and animals retards intrauterine growth. Science. 1978, 202: 436-438.PubMed

57.

Rodriguez-Pinilla E, Martinez-Frias ML: Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998, 58: 2-5. 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4.PubMed

58.

Carmichael SL, Shaw GM: Maternal corticosteroid use andrisk of selected congenital anomalies. Teratology. 1999, 86: 242-244.

59.

Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P, Contributors to the MADRE database: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003, 67: 968-970. 10.1002/bdra.10134.PubMed

60.

Czeizel AE, Rockenbauer M: Population-based case-controlstudy of teratogenic potential of corticosteroids. Teratology. 1997, 56: 335-340. 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W.PubMed

61.

Fraser FC, Sajoo A: Teratogenic potential of corticosteroids in humans. Teratology. 1995, 51: 45-46. 10.1002/tera.1420510107.PubMed

62.

Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, et al: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiologi-cal studies. Teratology. 2000, 62: 385-392. 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z.PubMed

63.

Källén B: Maternal drug use and infant cleft lip/palatewith special reference to corticoids. Cleft Pal Craniofacial J. 2003, 40: 624-628. 10.1597/02-077.

64.

Scott JR: Fetal growth retardation associated withmaternal administration of immunosuppressives. Am J Obstet Gynecol. 1977, 128: 668-676.PubMed

65.

Czeizel AE, Toth M: Birth weight, gestational age and medications during pregnancy. Int J Gynaecol Obstet. 1998, 60: 245-249. 10.1016/S0020-7292(97)00273-7.PubMed

66.

Schmidt PL, Sims ME, Strassner HT, Paul RH, Mueller E, McCart D: Effect of antepartum glucorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. Am J Obstet Gynecol. 1984, 178: 178-186.

67.

Cederqvist LL, Merkatz IR, Litwin SD: Fetal immunoglobinsynthesis following maternal immunosuppression. Am J Obstet Gynecol. 1977, 129: 687-690.PubMed

68.

Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW: Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993, 341: 339-341. 10.1016/0140-6736(93)90138-7.PubMed

69.

Kraus AM: Congenital cataract and maternal steroidinjection. J Pediatr Ophthalmol Strabismus. 1975, 12: 107-108.

70.

Coté CJ, Meuwissen HG, Pickering RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatrics. 1974, 85: 324-328.

71.

Price HV, Salaman JR, Laurence KM, Langmaid H: Immunusuppressive drugs and the fetus. Transplantation. 1976, 21: 294-298.PubMed

72.

National Institutes of Health: Report of the ConsensusDevelopment Conference on the Effect of Corticosteroids for FetalMaturation on Perinatal Outcome. NIH Publication no. 95–3784. 1994, Bethesda, MD: National Institute of Child Health and Human Development

73.

Huang WL, Haper CG, Evans SF, Newnham JP, Dunlop SA: Repeated prenatal corticosteroid administration delays astro-cyte and capillary tight junction maturation in fetal sheep. Int J Dev Neurosci. 2000, 19: 487-493. 10.1016/S0736-5748(01)00035-1.

74.

Matthews SG: Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res. 2000, 47: 291-300.PubMed

75.

Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG: Singleand repetitive maternal glucocorticoid exposures reduce fetal growthin sheep. Am J Obstet Gynecol. 1998, 178: 880-885. 10.1016/S0002-9378(98)70518-6.PubMed

76.

French NP, Hagan R, Evans SF, Godfrey M, Newnham JP: Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999, 180: 114-121. 10.1016/S0002-9378(99)70160-2.PubMed

77.

Abbasi S, Hirsch D, Davis J, Stouffer N, Debbs R, Gerdes JS: Effect of single versus multiple courses of antenatal corticos-teroids on maternal and neonatal outcome. Am J Obstet Gynecol. 2000, 182: 1243-1249. 10.1067/mob.2000.104789.PubMed

78.

Spinillo A, Viazzo F, Colleoni R, Chiara A, Cerbo RA, Fazzi E: Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol. 2004, 191: 217-224. 10.1016/j.ajog.2003.12.023.PubMed

79.

National Institutes of Health: Antenatal corticosteroid revisited: repeat courses. NIH Consensus Statement. 2000, 17: 1-18.

80.

Urban R, Lemancewicz A, Przepiesc J, Urban J, Kretowska M: Antenatal corticosteroid therapy: a comparative study of dex-amethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005, 120: 170-174. 10.1016/j.ejogrb.2004.09.009.PubMed

81.

Crowley P: Prophylactic corticosteroids for pretermdelivery. Cochrane Database Syst Rev. 2000, 2: CD000065-PubMed

82.

Jobe AH, Soll RF: Choice and dose of corticosteroid forantenatal treatments. Am J Obstet Gynecol. 2004, 190: 871-885. 10.1016/j.ajog.2004.01.044.

83.

Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, Groenendaal F, de Vries LS, Huppi PS: Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005, 116: 1-7. 10.1542/peds.2004-1275.PubMed

84.

Katz FH, Duncan BR: Entry of prednisone into human milk. N Engl J Med. 1975, 293: 1154-PubMed

85.

Öst L, Wettrell G, Bjorkhem I, Rane A: Prednisolone excretion in L, human milk. J Pediatrics. 1985, 106: 1008-1011. 10.1016/S0022-3476(85)80259-6.

86.

Ruiz-Irastorza G, Khamashta MA, Hughes GR: Heparin and osteoporosis during pregnancy: 2002 update. Lupus. 2002, 11: 680-682. 10.1191/0961203302lu262oa.PubMed

87.

Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A: Transplacental effcts of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999, 60: 68-73. 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H.PubMed

88.

Dunlop DJ, Soukop M, McEwan HP: Antenatal administrationof aminopropylidene diphosphonate. Ann Rheum Dis. 1990, 49: 955-PubMedCentralPubMed

89.

Illidge TM, Hussey M, Godden CW: Malignanthypercalciaemia – in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol. 1996, 8: 257-258. 10.1016/S0936-6555(05)80667-3.

90.

Rutgers-Verhage AR, de Vries TW, Torringa MJL: No effects of bisphosphonates on the human fetus. Birth Defects Res A. 2003, 67: 203-204. 10.1002/bdra.10016.

91.

Siminoski K, Fitzgerald AA, Flesch G, Gross MS: Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res. 2000, 15: 2052-2055. 10.1359/jbmr.2000.15.10.2052.PubMed

92.

Phillips-Howard PA, Wood D: The safety of antimalarial drugs in pregnancy. Drug Safety. 1996, 14: 131-145.PubMed

93.

Costedoat-Chalumeau N, Amoura Z, Aymard G, Huong DLT, Wechsler B, Vauthier D, Dermer ME, Darbois Y, Piette JC: Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002, 46: 1123-1124. 10.1002/art.10150.PubMed

94.

Wolfe MS, Cordero J: Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J. 1985, 290: 1466-1467.

95.

Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloro-quine. Am J Perinatol. 1991, 8: 174-178.PubMed

96.

Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol. 1988, 15: 607-610.PubMed

97.

Parke AL, West B: Hydoxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol. 1996, 23: 1715-1718.PubMed

98.

Buchanan NMM, Toubi E, Khamashta KE, Lima F, Kerslake S, Hughes GRV: Hydoxychloroquine and lupus pregnancy: review Jof a series of 36 cases. Ann Rheum Dis. 1996, 55: 486-488.PubMedCentralPubMed

99.

Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Seb-bough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003, 48: 3207-3211. 10.1002/art.11304.PubMed

100.

Borden MB, Parke AL: Antimalarial drugs in systemic lupus – erythematosus. Use in pregnancy. Drug Safety. 2001, 24: 1055-1063. 10.2165/00002018-200124140-00004.PubMed

101.

Hart CN, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg. 1964, 80: 407-412.

102.

Akintonwa A, Gbajumo SA, Mabadeje AFB: Placental and milk transfer of chloroquine in humans. Ther Drug Monit. 1988, 10: 147-149.PubMed

103.

Nation RL, Hackett LP, Dusci LJ, Ilett KF: Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol. 1984, 17: 368-369.PubMedCentralPubMed

104.

Østensen M, Brown ND, Chiang PK, Aarbakke J: Hydroxychloro-quine in human breast milk. Br J Clin Pharmacol. 1985, 28: 357-

105.

Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001, 358: 813-814. 10.1016/S0140-6736(01)06004-4.PubMed

106.

Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G: Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005, 25: 86-89. 10.1038/sj.jp.7211208.PubMed

107.

Cimaz R, Brucato A, Meregalli E, Muscarà M, Sergi P: Electroretinograms of children born to mothers treated with hydroxychloroquine (HCQ) during pregnancy and breast-feeding. Arthritis Rheum. 2004, 50: 3056-3057. 10.1002/art.20648.PubMed

108.

Borba EF, Turrini-Filho JR, Kuruma KA, Bertola C, Pedalini ME, Lorenzi MC, Bonfa E: Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004, 13: 223-227. 10.1191/0961203304lu528oa.PubMed

109.

Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT: Population based case control study of the safety of sul-phasalazine used during pregnancy. Aliment Pharmacol Ther. 2001, 15: 483-486. 10.1046/j.1365-2036.2001.00962.x.PubMed

110.

Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW: Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981, 80: 72-76.PubMed

111.

Järnerot G: Fertility, sterility and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol. 1982, 17: 1-4.PubMed

112.

Nielsen OH, Andreasson B, Bondesen S, Jarnum S: Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1993, 18: 735-742.

113.

Baocco PJ, Korelitz BI: The influence of inflammatorybowel disease and its treatment on pregnancy and on fetal outcome. J Clin Gastroenterol. 1984, 6: 211-216.

114.

Willoughby CP, Truelobe SC: Ulcerative colitis andpregnancy. Gut. 1980, 21: 469-474.PubMedCentralPubMed

115.

Moody GA, Probert C, Jayanthi V, Mayberry JF: The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorect Dis. 1997, 12: 220-224. 10.1007/s003840050093.

116.

Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000, 343: 1608-1614. 10.1056/NEJM200011303432204.PubMed

117.

Järnerot G, Anderson S, Esbjörner E, Sandström B, Brodersen R: Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol. 1981, 16: 1049-1055.PubMed

118.

Zwi LJ, Becroft DM: Intrauterine aplastic anemia andfetal hydrops: a case report. Pediatr Pathol. 1986, 5: 199-205.PubMed

119.

Levi S, Libermann M, Levi AJ, Bjarnason I: Reversible congenital neutropenia associated with maternal sulphasalazine therapy. Eur J Pediat. 1988, 148: 174-175. 10.1007/BF00445938.

120.

Esbjörner E, Järnerot G, Wranne L: Sulphasalazine andsul-phapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987, 76: 137-142.PubMed

121.

Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrah-mav A: Bloody diarrhoea – a possible complication of sul-phasalazine transferred through human breast milk. J Pediat Gastroenterol Nutr. 1986, 5: 316-317.

122.

O'Morain C, Smethurst P, Doré CJ, Levi AJ: Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984, 25: 1078-1084.PubMedCentralPubMed

123.

Brent RL: Teratogen update: reproductive risks of leflunomide (Arava). A pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001, 63: 106-112. 10.1002/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R.PubMed

124.

Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J Rheumatol. 2003, 30: 241-246.PubMed

125.

Polifka JE, Friedman JM: Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002, 65: 240-261. 10.1002/tera.10043.PubMed

126.

Reimers TJ, Sluss PM: 6-Mercaptopurine treatment ofpregnant mice: effect on second and third generation. Science. 1978, 201: 65-67.PubMed

127.

The Registration Committee of the European Dialysis andTransplant Association: Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol. 1980, 87: 839-845.

128.

Alstead EM, Ritchie JK, Leonard-Jones JE, Farthing MJG: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990, 99: 443-446.PubMed

129.

Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH: The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004, 99: 656-661. 10.1111/j.1572-0241.2004.04140.x.PubMed

130.

Price HV, Salaman JR, Laurence KM, Langmaid H: Immunusuppressive drugs and the fetus. Transplantation. 1976, 21: 294-298.PubMed

131.

Coté CJ, Meuwissen HG, Pickering RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatrics. 1974, 85: 324-328.

132.

Davison JM, Dellagrammatikas H, Parkin JM: Maternal azathio-prine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985, 92: 233-239.PubMed

133.

Rajapakse RO, Korelitz BI, Zlatank I, Baiocco PJ, Gleim GW: Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000, 95: 684-688. 10.1111/j.1572-0241.2000.01846.x.PubMed

134.

Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003, 124: 9-17. 10.1053/gast.2003.50014.PubMed

135.

Bennett PN: Azathioprine. Drugs and Human Lactation. Edited by: Bennett PN. 1988, Amsterdam: Elsevier, 286-287.

136.

Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, MoserH Stroemer G: Azathioprine treatment and male infertility in inflammatory bowel disease. Gastroenterology. 2001, 121: 1048-1053. 10.1053/gast.2001.28692.PubMed

137.

Pilarski LM, Yacyshyn BR, Lazarovits AI: Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. Transplantation. 1994, 57: 133-144.PubMed

138.

Scott JR, Branch WD, Holman J: Autoimmune and pregnancy complications in the daughter of a kidney transplant patient. Transplantation. 2002, 73: 815-816. 10.1097/00007890-200203150-00028.PubMed

139.

Schröder H, Fogh K: Methotrexate and its polyglutamatederivates in erythrocytes during and after weekly low-dose oralmethotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1988, 21: 145-149.PubMed

140.

Wilson JG, Scott WJ, Ritter EJ, Fradkin R: Comparativedistribution and embryo toxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology. 1979, 19: 71-98. 10.1002/tera.1420190111.PubMed

141.

Milunsky A, Graef JW, Gaynor MF: Methotrexate-induced congenital malformations. J Pediatrics. 1968, 72: 790-795. 10.1016/S0022-3476(68)80430-5.

142.

Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS: Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol. 2003, 101: 1104-1107. 10.1016/S0029-7844(03)00120-0.PubMed

143.

Powell HR, Eckert H: Methotrexate-induced congenital malformations. Med J Aust. 1971, 2: 1076-1077.PubMed

144.

Schleuning M, Clemm C: Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N Engl J Med. 1987, 317: 1666-1667.PubMed

145.

Pizzuto J, Aviles A, Noriega L, Niz J, Morales M, Romero F: Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep. 1980, 64: 679-683.PubMed

146.

Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990, 88: 589-592. 10.1016/0002-9343(90)90522-F.PubMed

147.

Feldkamp M, Carey JC: Clinical teratology counseling andconsultation case report: low dose methotrexate exposure in earlyweeks of pregnancy. Teratology. 1993, 47: 533-539. 10.1002/tera.1420470605.PubMed

148.

Donnenfeld AE, Pastuszak A, Salkoff Noah J, Schick B, Rose NC, Koren G: Methotrexate exposure prior to and during pregnancy. Teratology. 1994, 49: 79-81. 10.1002/tera.1420490202.PubMed

149.

Buckley LM, Bullaboy CA, Leichtman L, Marquez M: Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum. 1997, 40: 971-973.PubMed

150.

Østensen M, Hartmann H, Salvesen K: Low dose weeklymethotrexate in early pregnancy. A case series and review of the literature. J Rheumatol. 2000, 27: 1872-1875.PubMed

151.

Krähenmann F, Østensen M, Stallmach Th, Huch A, Chaoui R: In utero first trimester exposure to low-dosemethotrexate with increased fetal nuchal translucency and associatedmalformations. Prenat Diagn. 2002, 22: 489-490. 10.1002/pd.334.PubMed

152.

Rustin GJS, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD: Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J. 1984, 288: 103-106.

153.

Gervaise A, Masson L, de Tayrac R, Frydman R, Fernandez H: Reproductive outcome after methotrexate treatment of tubal pregnancies. Obstet Gynecol Surv. 2005, 60: 175-176. 10.1097/01.ogx.0000156073.30008.1a.

154.

Green DM, Zevon MA, Lowrie G, Seigelstein N, Hall B: Congenital anomalies in children of patients who received chemotherapy for cancer in childhood and adolescence. N Engl J Med. 1991, 325: 141-146.PubMed

155.

Johns DG, Rutherford LD, Keighton PC, Vogel CL: Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972, 112: 978-980.PubMed

156.

Morris LF, Harrod MJ, Menter MA, Silverman AK: Methotrexate and reproduction in men: Case report and recommendations. J Am Acad Dermatol. 1993, 29: 913-916.PubMed

157.

Sussman A, Leonard JM: Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980, 116: 215-217. 10.1001/archderm.116.2.215.PubMed

158.

Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R, Garcia EL: Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol. 1991, 36: 243-248.PubMed

159.

Mirkes PE: Cyclophosphamide teratogenesis. A review. Teratogen Carcinogen Mutagen. 1985, 5: 75-88. 10.1002/tcm.1770050202.

160.

Greenberg LH, Tanaka KR: Congenital anomalies probablyinduced by cyclophosphamide. JAMA. 1964, 188: 423-426.PubMed

161.

Toledo TM, Harper RC, Moser RH: Fetal effects duringcyclophosphamide and irradiation therapy. Ann Intern Med. 1971, 74: 87-91.PubMed

162.

Murray CL, Reichert JA, Anderson J, Twiggs LB: Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA. 1984, 252: 2607-2608. 10.1001/jama.252.18.2607.PubMed

163.

Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER: Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988, 72: 462-464.PubMed

164.

Zemlickis D, Lishner M, Erlich R, Koren G: Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophos-phamide. Teratogen Carcinogen Mutagen. 1993, 13: 139-143. 10.1002/tcm.1770130304.

165.

Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G: Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992, 152: 573-576. 10.1001/archinte.152.3.573.PubMed

166.

Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M: Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. Am J Med Genet. 1999, 86: 237-241. 10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V.PubMed

167.

Paladini D, Vassallo M, D'Armiento MR, Cianciaruso B, Martinelli P: Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol. 2004, 70: 99-100. 10.1002/bdra.10147.PubMed

168.

Vaux KK, Kahole NC, Jones KL: Cyclophosphamide, methotrex-ate, and cytarabine embropathy: is apoptosis the common pathway?. Birth Defects Res A Clin Mol Teratol. 2003, 67: 403-408. 10.1002/bdra.10060.PubMed

169.

Durodola JI: Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Nat Med Ass. 1979, 71: 165-166.PubMedCentralPubMed

170.

Gershenson DM: Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988, 6: 270-275.PubMed

171.

Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, Pendergrass TW, Robison LL: Pregnancy outcome ofpartners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003, 21: 716-721. 10.1200/JCO.2003.04.085.PubMed

172.

Wiernik PH, Duncan JH: Cyclophosphamide in human milk. Lancet. 1971, i: 912-10.1016/S0140-6736(71)92474-3.

173.

Waxman J: Chemotherapy and the adult gonad: a review. J R Soc Med. 1983, 76: 144-148.PubMedCentralPubMed

174.

Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk of sustained amenorrhea in patients with systemiclupus erythematosus receiving intermittent pulse cyl-cophosphamidetherapy. Ann Intern Med. 1993, 119: 366-369.PubMed

175.

Huong DLT, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC: Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002, 29: 2571-2576.PubMed

176.

Silva CAA, Hallak J, Pasqualotto FF, Barba MF, Saito MI, Kiss MHB: Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol. 2002, 29: 2000-2005.PubMed

177.

Kenney LB, Laufer MR, Grant FD, Grier H, Diller L: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001, 91: 613-621. 10.1002/1097-0142(20010201)91:3<613::AID-CNCR1042>3.0.CO;2-R.PubMed

178.

Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ: Use of a gonadotropin-releasing hormone analog against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005, 52: 2761-2767. 10.1002/art.21263.PubMed

179.

Winter JF, Boice JD, Mulvihill JJ, Stovall M, Frederiksen K, Tawn EJ, Olsen JH: Chromosomal abnormalities among offspring of child-cancer survivors in Denmark: a population based study. Am J Hum Genet. 2004, 74: 1282-1285. 10.1086/421473.

180.

Mason RJ, Thomson AW, Whiting PH, Gray ES, Brown PA, Catto GRD, Simpson JG: Cyclosporine-induced fetotoxicity in the rat. Transplantation. 1985, 39: 9-12.PubMed

181.

Cockburn I, Krupp P, Monka C: Present experience of Sandim-mun in pregnancy. Transplant Proc. 1989, 21: 3730-3732.PubMed

182.

Hussein MM, Mooij JMV, Roujouleh H: Cyclosporine in the treatment of lupus nephritis including 2 patients treated during pregnancy. Clin Nephrol. 1993, 40: 160-163.PubMed

183.

Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF: National transplantation pregnancy registry:outcomes of 154 pregnancies in cyclosporine-treated female kidneytransplant recipients. Transplantation. 1994, 57: 502-506.PubMed

184.

Lamarque V, Leleu MF, Monka C, Krupp P: Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandim-mun. Transplant Proc. 1997, 29: 2480-10.1016/S0041-1345(97)00458-2.PubMed

185.

Barrou BM, Gruessner AC, Sutherland DE, Gruessner RW: Pregnancy after pancreas transplantation in the cyclosporin era: report from the International Pancreas Transplant Registry. Transplantation. 1998, 65: 524-527. 10.1097/00007890-199802270-00012.PubMed

186.

Shaheen FAM, AI-Sulaiman MH, AI-Khader AA: Long-termnephrotoxicity after exposure to CsA in utero. Transplantation. 1993, 56: 224-225.PubMed

187.

Bar Oz B, Hackman R, Einarson T, Koren G: Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation. 2001, 71: 1051-1055. 10.1097/00007890-200104270-00006.PubMed

188.

Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S: Cyclosporine excretion into breast milk. Transplantation. 2003, 75: 2144-2146. 10.1097/01.TP.0000066352.86763.D0.PubMed

189.

Stanley CW, Gottlieb R, Zager R, Eisenberg J, Richmond R, Moritz MJ, Armenti VT: Developmental well-being in offspring of women receiving post-renal transplant. Transplant Proc. 1999, 31: 241-242. 10.1016/S0041-1345(98)01519-X.PubMed

190.

Di Paolo S, Schena A, Morrone LF, Manfredi G, Stallone G, Derosa C, Procino A, Schena FP: Immunologic evaluation during the first year of life of infants born to cyclosporine treated female kidney transplant recipients. Transplantation. 2000, 69: 2049-2054. 10.1097/00007890-200005270-00013.PubMed

191.

Cimaz R, Meregalli E, Biggioggero M, Borghi O, Tincani A, Motta M, Airo P, Meroni PL: Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett. 2004, 149: 155-162. 10.1016/j.toxlet.2003.12.030.PubMed

192.

Sgro MD, Barrozino T, Mirghani HM, Sermer M, Moscato L, Akoury H, Koren G, Chitayat D: Pregnancy outcome post renal transplantation. Teratology. 2002, 65: 5-9. 10.1002/tera.1092.PubMed

193.

Jain AB, Shapiro R, Scantlebury VP, Potdar S, Jordan ML, Flohr J, Marcos A, Fung JJ: Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation. 2004, 77: 897-902. 10.1097/01.TP.0000117564.50117.FB.PubMed

194.

Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW, de Vera ME, Rafail A, et al: Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003, 76: 827-832. 10.1097/01.TP.0000084823.89528.89.PubMedCentralPubMed

195.

Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D: Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000, 70: 1718-1721. 10.1097/00007890-200012270-00010.PubMed

196.

Miniero R, Tardivo I, Curtoni ES, Segoloni GP, La Rocca E, Nino A, Todeschini P, Tregnaghi C, Rosati A, Zanelli P, Dall'Omo AM: Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol. 2002, 15: 626-632.PubMed

197.

French AE, Soldin SJ, Soldin OP, Koren G: Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003, 37: 815-818. 10.1345/aph.1C312.PubMedCentralPubMed

198.

Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F: Mycophenolate mofetil in pregnancy after renal transplantation: a case of major foetal malformations. Obstet Gynecol. 2004, 103: 1091-1094.PubMed

199.

Pergola PE, Kancharla A, Riley DJ: Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation. 2001, 71: 994-997. 10.1097/00007890-200104150-00028.PubMed

200.

Armenti VT, Radomski JS, Gaughan WJ, Philips LZ, McGrory CH, Coscia LA, National Transplantation Registry: Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2003, 17: 131-141.

201.

Radder CM, Roelen DL, van de Meer-Prins, Claas FH, Kanhai HH, Brand A: The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2004, 191: 815-820. 10.1016/j.ajog.2004.02.002.PubMed

202.

Vesga L, Terdiman JP, Mahadevan U: Adalimumab use in pregnancy. Gut. 2005, 54: 890-10.1136/gut.2005.065417.PubMedCentralPubMed

203.

Sanchez Munoz D, Hoyas Pablos E, Ramirez Martin Del Campo M, Nunez Hospital D, Guerrero Jimenez P: Term pregnancy in a patient with Crohn's disease under treatment with adali-mumab. Gastroenterol Hepatol. 2005, 28: 435-10.1157/13077767.PubMed

204.

Herold M, Schnohr S, Bittrich H: Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2001, 19: 3439-PubMed

205.

Kimby E, Sverrisdottir A, Elinder G: Safety of rituximabtherapy during the first trimester of pregnancy: a case history. Eur J Haematol. 2004, 72: 292-295. 10.1111/j.1600-0609.2004.00214.x.PubMed

206.

Goroir BP, Peppel K, Silva M, Beutler B: The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw. 1992, 3: 533-537.

207.

Hyrich K, Symmons D, Watson K, Silman A: Pregnancyoutcome in women who were exposed to anti-TNF agents: Results from anational population register. Arthritis Rheum.

208.

Østensen M, Eigenmann GO: Etanercept in breast milk. J Rheumatol. 2004, 31: 1017-1018.PubMed

209.

Treacy G: Using an analogous monoclonal antibody toevaluate the reproductive and chronic toxicity potential for a humanized anti-TNF-α monoclonal antibody. Hum Exp Toxicol. 2000, 19: 226-228. 10.1191/096032700678815765.PubMed

210.

Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Ter-diman JP, Binion DG: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005, 21: 733-738. 10.1111/j.1365-2036.2005.02405.x.PubMed

211.

Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004, 99: 2385-2392. 10.1111/j.1572-0241.2004.30186.x.PubMed

212.

Förger F, Matthias T, Oppermann M, Østensen M, Helmke K: Infliximab in breast milk. Lupus. 2004, 13: 753-10.1191/0961203304lu485oa.

213.

Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P: Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005, 11: 395-399. 10.1097/01.MIB.0000164023.10848.c4.PubMed

Titel: Anti-inflammatory and immunosuppressive drugs and reproduction
verfasst von: Monika Østensen
Munther Khamashta
Michael Lockshin
Ann Parke
Antonio Brucato
Howard Carp
Andrea Doria
Raj Rai
Pierluigi Meroni
Irene Cetin
Ronald Derksen
Ware Branch
Mario Motta
Caroline Gordon
Guillermo Ruiz-Irastorza
Arsenio Spinillo
Deborah Friedman
Rolando Cimaz
Andrew Czeizel
Jean Charles Piette
Ricard Cervera
Roger A Levy
Maurizio Clementi
Sara De Carolis
Michelle Petri
Yehuda Shoenfeld
David Faden
Guido Valesini
Angela Tincani
Publikationsdatum: 01.06.2006
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 3/2006
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1957

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Anti-inflammatory and immunosuppressive drugs and reproduction

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production

Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis

Conventional radiography requires a MRI-estimated bone volume loss of 20% to 30% to allow certain detection of bone erosions in rheumatoid arthritis metacarpophalangeal joints

Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients

The matrix-forming phenotype of cultured human meniscus cells is enhanced after culture with fibroblast growth factor 2 and is further stimulated by hypoxia

Reshaping Cinderella's slipper: the shared epitope hypothesis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin